Skip to main content

Table 2 Effect of Doxorubicin (DOX) and different treatments of AHE on hepatic POD, SOD, CAT and QR status

From: Effect of Acacia hydaspica R. Parker extract on lipid peroxidation, antioxidant status, liver function test and histopathology in doxorubicin treated rats

Treatment (mg/kg) POD (U/min) SOD (U/mg protein) CAT (U/min) QR (nM/min/mg protein)
Control 13.40 ± 0.225b 1.547 ± 0.0592b 24.02 ± 0.077b 104.8 ± 1.006b
DOX 6.090 ± 0.589a 0.3824 ± 0.054a 12.72 ± 0.044a 64.79 ± 1.070a
AHE alone 13.09 ± 0.266b 1.553 ± 0.0814b 24.03 ± 0.026b 104.7 ± 1.065b
DOX + AHE (200) 9.06 ± 0.271a, b, d 1.063 ± 0.0364a**, b 15.43 ± 0.063a, b, d 76.81 ± 0.476a, b, d
DOX + AHE (400) 12.09 ± 0.179b, c 1.371 ± 0.0794b, c* 20.83 ± 0.058a, b, c 94.87 ± 1.433a, b, c
DOX + Sily 12.20 ± 0.237b 1.323 ± 0.0566b 20.90 ± 0.088a, b 93.40 ± 1.440a, b
  1. Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. *, ** Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin